Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research

Emaad Khansur, Ashish H. Shah, Kyle Lacy, Ricardo J. Komotar

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCancer Investigation
Issue number1
StatePublished - Jan 2 2019


  • Clinical trial
  • Glioblastoma
  • Immunotherapy
  • Novel
  • Outcomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research'. Together they form a unique fingerprint.

Cite this